Results 51 to 60 of about 7,581 (239)

Failure of ceftolozane‐tazobactam salvage therapy in complicated pneumonia with lung abscess

Clinical Case Reports, 2018
Key Clinical Message Treatment of Pseudomonas aeruginosa remains challenging, despite the availability ceftolozane‐tazobactam. We report a treatment failure with ceftolozane‐tazobactam salvage therapy for pneumonia complicated by lung abscess.
Paul O. Lewis, David B. Cluck, Jennifer L. Tharp, Matthew A. Krolikowski, Paras D. Patel   +4 more
doaj   +1 more source

Cost-effectiveness of ceftolozane/tazobactam compared with piperacillin/tazobactam as empiric therapy based on the in-vitro surveillance of bacterial isolates in the United States for the treatment of complicated urinary tract infections

BMC Infectious Diseases, 2017
Background A challenge in the empiric treatment of complicated urinary tract infection (cUTI) is identifying the initial appropriate antibiotic therapy (IAAT), which is associated with reduced length of stay and mortality compared with initial ...
Teresa L Kauf, Vimalanand S. Prabhu, Goran Medic, Rebekah H. Borse, Benjamin Miller, Jennifer Gaultney, Shuvayu S. Sen, Anirban Basu   +7 more
doaj   +1 more source

Extended-spectrum beta-lactamase-producing enterobacteriaceae : epidemiology and dynamics of fecal carriage [PDF]

, 2013
ESBL-producing Enterobacteriaceae (EPE) has become a major cause of community acquired urinary tract infection (UTI), and fecal carriage of EPE is emerging worldwide.
Titelman, Emilia
core   +1 more source

Clinical Characteristics, Microbiology and Outcomes of a Cohort of Patients Treated with Ceftolozane/Tazobactam in Acute Care Inpatient Facilities, Houston, Texas, USA [PDF]

, 2023
BACKGROUND: Ceftolozane/tazobactam is a β-lactam/β-lactamase inhibitor combination with activity against a variety of Gram-negative bacteria, including MDR METHODS: We conducted a multicentre retrospective study of patients receiving at least 48 h of ...
Aitken, Samuel L, Alnezary, Faris, Arias, Cesar A, Cabrera, Nicolo L, Carlson, Travis J, Diaz, Lorena, Dillon, Ryan, Dinh, An Q, Garey, Kevin W, Gonzales-Luna, Anne J, Hanson, Blake M, Miller, William R, Munita, Jose M, Pedroza, Claudia, Puzniak, Laura, Rios, Rafael, Rydell, Kirsten, Sakurai, Aki, Shelburne, Samuel A, Tran, Truc T   +19 more
core   +5 more sources

Comparing ceftolozane/tazobactam versus piperacillin/tazobactam as empiric therapy for complicated urinary tract infection in Taiwan: A cost-utility model focusing on gram-negative bacteria

Journal of Microbiology, Immunology and Infection, 2019
Background: Complicated urinary tract infection (cUTI) is often associated with drug-resistant pathogens and requires therapy with broad-spectrum antibiotics.
Guan-Jhou Chen, Sung-Ching Pan, Jason Foo, Chaienna Morel, Wei-Ting Chen, Jann-Tay Wang   +5 more
doaj   +1 more source

The continued value of disk diffusion for assessing antimicrobial susceptibility in clinical laboratories: Report from the Clinical and Laboratory Standards Institute Methods Development and Standardization Working Group [PDF]

, 2018
Expedited pathways to antimicrobial agent approval by the U.S. Food and Drug Administration (FDA) have led to increased delays between drug approval and the availability of FDA-cleared antimicrobial susceptibility testing (AST) devices.
Burnham, Carey-Ann D, Ferrell, Andrea, Hsiung, Andre, Humphries, Romney M, Kircher, Susan, Krause, Kevin M, Malherbe, Rianna   +6 more
core   +2 more sources

Comparison of antimicrobial activity between ceftolozane–tazobactam and ceftazidime–avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa

International Journal of Infectious Diseases, 2017
Objective: This study compared the activity of ceftolozane–tazobactam and ceftazidime–avibactam against 120 bacterial strains, including extended-spectrum beta-lactamase (ESBL) producers, carbapenem-resistant Enterobacteriaceae (CRE), and Pseudomonas ...
Adnan Alatoom, Hashim Elsayed, Karen Lawlor, Laila AbdelWareth, Rania El-Lababidi, Lysettee Cardona, Mohammad Mooty, Maria-Fernanda Bonilla, Ahmad Nusair, Imran Mirza   +9 more
doaj   +1 more source

Potential of high-dose cefepime/tazobactam against multi-resistant Gram-negative pathogens [PDF]

, 2017
Background: Early β-lactamase inhibitors were combined with established penicillins, but different combinations may be more appropriate to counter current β-lactamase threats, with development facilitated by the US Generating Antibiotic Incentives Now ...
Livermore, David M, Mushtaq, Shazad, Turner, Simon J, Warner, Marina, Woodford, Neil   +4 more
core   +1 more source

Satisfactory In Vitro Activity of Ceftolozane–Tazobactam against Carbapenem-Resistant Pseudomonas aeruginosa But Not against Klebsiella pneumoniae Isolates

Medicina, 2023
Background: Gram-negative rods are one of the most commonly isolated bacteria within human infections. These microorganisms are typically opportunistic pathogens that pose a serious threat to public health due to the possibility of transmission in the ...
Alicja Sękowska, Marta Grabowska, Tomasz Bogiel   +2 more
doaj   +1 more source

Treatment of infections caused by multidrug-resistant Gram-negative bacteria:Report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party [PDF]

, 2018
The Working Party makes more than 100 tabulated recommendations in antimicrobial prescribing for the treatment of infections caused by multidrug-resistant (MDR) Gram-negative bacteria (GNB) and suggest further research, and algorithms for hospital and ...
Enoch, David A, Hawkey, Peter M, Livermore, David M, McNulty, Cliodna A M, Otter, Jonathan A, Warren, Roderic E, Wilson, A Peter R   +6 more
core   +1 more source